MediPharm Labs (TSE:LABS)
TSX:LABS
Earnings Data
Report Date
May 18, 2026TBA (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
―Last Year’s EPS
0Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Q4 2025
Earnings Call Date:Mar 30, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call presented a predominantly positive operational and strategic trajectory: revenue growth (8% YoY) driven by a 43% increase in international medical, margin improvements (Q4 gross margin 35%), cost reductions, stronger liquidity (cash $10.8M) and clear product and market progress (new market entries and pharma-grade launches). However, notable negatives remain — continued net losses (-$8.3M), Q4 revenue dip vs prior year, ongoing pricing compression in key markets, an upcoming Veterans Affairs reimbursement cut, and an interim CEO transition. Taken together, the positives around international growth, regulatory differentiation, expense discipline and strengthened balance sheet materially outweigh the challenges, although risks and near-term headwinds persist.Company Guidance
Full Year Revenue Growth
Full year 2025 revenue of $45.1M, up 8% year-over-year, the highest revenue in five years.
International Medical Cannabis Expansion
International medical cannabis grew 43% year-over-year and represented over 50% of total revenue during Q1–Q3 and 55% in Q4, becoming the largest revenue stream.
Gross Profit and Margin Improvement
Full year gross profit of $14.0M with a 31% gross margin. Q4 gross profit of $3.9M (35% margin), up from $3.6M (30%) in Q4 2024 — improvement driven by favorable product mix and cost reductions.
Progress Toward Profitability
Adjusted EBITDA loss improved to -$1.6M in 2025 from -$1.9M in 2024. Net loss narrowed to -$8.3M from -$10.7M in 2024.
Stronger Balance Sheet and Liquidity
Ended FY2025 with $10.8M in cash (up $0.2M from Q3), virtually no debt, and ownership of two production facilities with appraised value exceeding $15M.
Cost Discipline and Operating Expense Reduction
Total operating expenses decreased to $20.9M (including discrete items). Adjusted YTD operating expenses were $16.8M, down $2.7M or 14% versus prior year; Q4 adjusted operating expenses (ex-severance) declined 8% year-over-year.
Strategic Asset Monetization and Capacity Investment
Completed $4.5M sale of noncore Hope BC facility and invested to expand EU‑GMP Napanee capacity by ~30%, now operational.
Regulatory and Manufacturing Differentiation
Holds a strong suite of regulatory credentials (Health Canada Drug Establishment license, EU‑GMP, ANVISA GMP, TGA compliance, FDA‑inspected facility) enabling access to regulated markets and pharmaceutical/B2B opportunities.
Product and Market Execution
Commercial launches and first shipments: first commercial shipments into France, first purchase orders in Brazil under ANVISA partner, approvals and initial shipments for New Zealand, launch of CBN‑THC nighttime inhaler in Canada, and four metered dose inhaler products plus a high‑CBD cartridge in Australia.
Receivables and Payables Discipline
Trade and other receivables of $7.5M with 85% aged 60 days or less; up‑to‑date on excise duties, sales taxes and trade payables (trade and other payables $9.2M).
TSE:LABS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TSE:LABS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 30, 2026 | C$0.07 | C$0.07 | 0.00% |
Nov 13, 2025 | C$0.07 | C$0.07 | 0.00% |
Aug 14, 2025 | C$0.09 | C$0.08 | -11.11% |
May 14, 2025 | C$0.10 | C$0.10 | +5.26% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does MediPharm Labs (TSE:LABS) report earnings?
MediPharm Labs (TSE:LABS) is schdueled to report earning on May 18, 2026, TBA (Confirmed).
What is MediPharm Labs (TSE:LABS) earnings time?
MediPharm Labs (TSE:LABS) earnings time is at May 18, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TSE:LABS EPS forecast?
Currently, no data Available